Remynd

Developer of a drug pipeline programs for neurodegenerative diseases

placeLeuven, Flemish Region, Belgium calendar_todayFounded 2002 groups46 employees language remynd.com

Registered entities

Innovation

17 patent families (14 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace slowing. Cited 699 times.

YearFilings
20124
20137
20144
20155
20165
20176
20182
20192
20207
20221

Social engagement

Social engagement: 3.6K social following, 7 posts in the last 12 months — below the industry typical range.

Investor mix

8 investors on record; lead investors include PMV, Korys, SFPI.

Investor typeCountShare
Private equity225%
Bank & private debt113%
Other / undisclosed563%

Recent activity

6 Oct 2025
Event
SACHS25
Coming soon